Coronary Microvascular Disease: Small-Vessel Angina, Testing and Treatment

Direct answer. Coronary microvascular disease affects the small vessels supplying heart muscle. It can cause clinically important angina even when an angiogram does not show a major obstructive narrowing in a large coronary artery. Diagnosis may require selected tests of perfusion or vessel function, and treatment should address the established pattern and the person’s wider risks.

Evidence summary

Confidence is high in the condition distinctions and need for appropriate assessment. The treatment section attributes clinical guidance; it does not certify the funding of every underlying intervention trial. Independent comparative outcome certainty and a supplement replacement regimen were not established by this focused review. A public institution or independent review cannot make a sponsored original trial financially independent.

What it is

NHLBI includes coronary microvascular disease among coronary heart-disease patterns. The small vessels can fail to regulate blood supply appropriately. “Coronary microvascular dysfunction,” often abbreviated CMD, describes this functional problem. Microvascular angina refers to angina associated with the small-vessel pattern; the terms do not mean that every chest symptom with an unobstructed angiogram has the same cause. NHLBI coronary disease; NHLBI angina types.

The small coronary vessels differ from the large arteries that are visible in a conventional angiogram. The condition also differs from cerebral small-vessel disease, peripheral circulation problems and a generic microbiome or inflammation theory. Precision in the diagnosis helps explain which tests and treatments are relevant.

How it works

Heart muscle needs blood delivery to match changing oxygen demand. Abnormal small-vessel dilation or regulation can limit that delivery. A person may experience discomfort during exertion or at rest; NHLBI notes that microvascular episodes can be longer and more painful than other angina patterns. A symptom description alone cannot establish the mechanism. NHLBI angina types.

The distinction between structure and function matters. A scan that shows no major narrowing answers an important question about the larger arteries, but does not necessarily measure small-vessel behaviour. Conversely, a test suggesting abnormal perfusion needs clinical interpretation and consideration of other causes. NHLBI coronary diagnosis.

The evidence-based treatments

Assessment begins with symptoms, medical history and relevant risk factors. NHLBI describes selected PET or other imaging to assess flow, and additional tests when symptoms persist despite apparently unobstructed coronary arteries. Not everyone needs every test, and a result should be explained in terms of what it adds to the diagnosis. NHLBI coronary diagnosis.

NHLBI lists options such as beta blockers, calcium-channel blockers, nitrates, ACE inhibitors or ARBs, and ranolazine in the small-vessel care context. The actual choice depends on the pattern, blood pressure, other illnesses and medication tolerance. This list attributes a public treatment framework; it is not a brand ranking or proof that every option has equal independent outcome evidence. NHLBI coronary treatment.

The team may separately manage cholesterol, hypertension or diabetes where those are relevant. Symptom improvement and long-term event prevention are different outcomes. A medication can be prescribed for a coexisting indication even when it is not the main treatment for the small-vessel symptom mechanism. NHLBI coronary treatment.

Large-artery procedures require an appropriate target and clinical indication. An absence of a target for a stent does not make symptoms imaginary, and it does not imply that all treatment has failed. The next useful question is which mechanism is supported and which outcome will be monitored. NHLBI coronary diagnosis.

Supplement and lifestyle evidence

Smoking cessation, management of relevant blood pressure, lipid and glucose problems, an appropriate eating pattern and a clinician-agreed activity plan are parts of coronary care. Adjust activity according to symptoms and the care plan rather than exercising through new concerning pain. NHLBI coronary treatment; NHS angina.

No supplement is established here as a treatment for coronary microvascular disease. “Heart support,” improved vessel relaxation, a changed blood marker and fewer clinical events are different claims. The cited source set does not provide a fully financially screened trial basis for replacing diagnosis or prescribed care. Correcting a clinician-confirmed deficiency is a separate indication; a retail blend is not a diagnostic test or an emergency treatment.

What works and what does not

Useful care acknowledges persistent symptoms, distinguishes the large-vessel and small-vessel questions and states a follow-up goal. “Normal angiogram” and “no cardiac cause” should not be treated as interchangeable conclusions.

Ask which outcome is being pursued: symptoms, physiological findings, recurrence, hospital admission or survival. A plan should also say how adverse effects and deterioration will be recognized. Personal stories and before-and-after readings cannot separate treatment effects from the natural course, other medicines or selection of patients. Manufacturer or materially conflicted outcome claims do not determine this article’s independent verdict.

Risks and side effects

New, substantially worse or persistent chest symptoms need appropriate urgent assessment; do not assume that every episode is explained by the existing microvascular label. Severe breathlessness, faintness or symptoms suggesting a heart attack require the local emergency service. NHLBI heart attack symptoms.

Antianginal treatment can cause dizziness, headache, gastrointestinal symptoms or low blood pressure, depending on the drug. Tests involving catheters or contrast also have risks. The choice of treatment and investigation should consider what question is being answered and whether the result will change care. NHLBI angina treatment; NHLBI coronary diagnosis.

Important interactions

Several antianginal and blood-pressure medicines can have overlapping effects. Nitrates require specific review alongside erectile-dysfunction medicines, and a medication list should include all non-prescription products. A pharmacist can check the precise combination rather than infer safety from the product category. NHS GTN interactions, April 2023.

Bring prescription medicines, non-prescription products, recreational drugs and supplements to the same medication review. Product names alone may hide several active ingredients. The prescriber or pharmacist should check the exact combination and kidney function, rather than treating “natural” as a safety category. Never add a second person’s rescue medicine or stop an important prescribed medicine because an internet list mentions a possible interaction.

Who needs assessment

People with persistent symptoms after apparently reassuring anatomical tests should avoid treating the result as a complete explanation of every possible mechanism. Follow-up should consider the whole clinical picture. This is different from ordering repeated scans without a defined question. NHLBI coronary diagnosis.

A home ECG, calcium score, exercise sensation or dietary experiment should not be used to diagnose CMD. People with kidney disease, low blood pressure or several medicines need individualized testing and medication review. NHLBI coronary diagnosis.

Clinician-led use and follow-up

Record whether the diagnosis is suspected or confirmed, what the relevant test demonstrated and which symptoms or activities should improve. If a treatment does not help, review the mechanism and tolerability rather than automatically stacking another supplement. NHLBI coronary diagnosis.

This guide gives no personal drug, device or supplement dose. The appropriate plan depends on the established diagnosis, current stability, other illnesses and local services. Ask for a written explanation of the treatment purpose, warning signs, review schedule and contact route for side effects. Clinical monitoring and informed consent should accompany any change; study exposures are not prescriptions.

Animal and in-vitro evidence

Cell and animal experiments on vessel function or cardiac stress can suggest mechanisms. They do not establish safe human dosing, symptom improvement or fewer serious events. A laboratory preparation and a retail product may differ in composition, absorption and exposure. No animal or in-vitro result contributes to the independent clinical verdict in this guide.

Funding and source roles

Small-vessel symptoms generate demand for advanced imaging, coronary-function tests, antianginal medicines and “endothelial support” products. Tests and drugs have legitimate clinical roles, but their commercial availability does not establish a universal benefit or an independent supplement replacement.

The condition has no corporate owner. Medicines, diagnostics, devices, procedures and marketed supplements create different revenue incentives. This describes financial interests rather than misconduct. Funding tier evaluates proximity to the subject; A–D credibility assesses transparency, accuracy incentives and remaining uncertainty. An unresolved link stays unresolved, and a provisional public-information label does not clear the trials behind it.

Frequently asked questions

Is this the same as a blocked major artery?
It affects the small-vessel circulation, although coronary patterns can coexist. NHLBI coronary disease.

Can an angiogram look unobstructed?
Yes; additional selected functional assessment may be needed. NHLBI coronary diagnosis.

Does a stent treat every case?
A procedure needs an appropriate anatomical target and indication. NHLBI coronary diagnosis.

What should follow-up measure?
The agreed symptom, activity and risk-factor goals, together with medicine tolerability and warning signs.

Sources and funding notes

• NHLBI coronary disease — Disease patterns and small-vessel dysfunction.
• NHLBI angina types — Microvascular angina pattern.
• NHLBI coronary diagnosis — Specific perfusion and vessel-function testing.
• NHLBI coronary treatment — Attributed small-vessel treatment options.
• NHLBI angina treatment — Symptom treatment and medicine adverse effects.
• NHS angina — UK symptom and activity context.
• NHLBI heart attack symptoms — Emergency distinction.
• NHS GTN interactions, April 2023 — Dated direct medicine-interaction safety context.
• NHLBI budget — Financial provenance only.
• NHLBI Gift Fund — Financial provenance only.
• NHS national website funding policy — Financial provenance only.

Original clinical pages and their relevant financial disclosures were opened. Where cited, the 2026 definition was read through the web tool; its author supplement was inaccessible and remains an explicit gap. Where cited, the 2018 SCAD papers were read in original full versions, including funding and disclosure tables. Guidance, classification, emergency education and independent efficacy are distinct source roles. A full systematic review, complete society donor audit and author-by-author clearance of original treatment trials were not completed.

Last reviewed: October 4, 2026. Educational information, not a diagnosis or personal treatment plan. Use your local emergency service for an emergency.